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Primary surgery with gastrectomy and, if feasible,
with extended D2 node dissection is the current
standard treatment of operable gastric cancer.1,2
However, it is widely accepted that without adjuvant
systemic treatment, the high relapse and death rates
can hardly be improved. Despite research efforts,
neither a chemotherapeutic regimen nor the timing of
chemotherapy administration (i.e., before or after
surgery) has been standardized. For the ﬁrst time
now, the MAGIC trial provides level I evidence for a
survival beneﬁt of perioperative chemotherapy over
surgery alone in patients with localized gastric can-
cer.3 However, this study raises several questions:
given that it was designed to assess an overall beneﬁt
and not a stage-speciﬁc survival beneﬁt, it remains
unknown as to which subgroups (II, IIIA or IIIB)
mostly beneﬁt from a perioperative regimen of epi-
rubicin, cisplatin, and infused ﬂuorouracil (ECF).
Another key question is the impact of the MAGIC
study in daily clinical practice. As several treatment
options become available, uncertainty of oncologists
for selecting an optimal adjuvant chemotherapy be-
tween perioperative, neoadjuvant and postoperative
setting increases.
Gastric cancer is an aggressive malignancy with
nearly 700,000 deaths annually (the second leading
cause of cancer death) and a prevalence of around
930,000 new patients annually worldwide.4 Even the
most appropriate local therapy, as an extensive D2/
D3 surgery,5 which increases6,7 the rate of a true
complete surgical pathologic R0 resection,8 is asso-
ciated with a substantial proportion of recurrence
and death.9 Particularly in patients with advanced
serosa-positive, node-positive gastric cancer, the 10-
year survival rate ranges between 10%10 and, at best,
30%.5 Overall, less than 30% of Western patients are
cured with local therapy alone as an R0 resec-
tion.10–13 Systemic adjuvant treatment is required for
survival improvements.
The biological and clinical heterogeneity of gastric
cancer represents a major challenge of current and
future molecular and clinical research. 14,15 Clinical
data provide differential outcomes among patients
with same TNM stage (I, II or III) and treatment7–9
and thus there is a clear requirement for tailoring
adjuvant systemic therapy in treating speciﬁc sub-
groups of patients.15,16 Clinical models converted into
a software program using conventional clinicopath-
ologic prognostic factors have been developed and
validated,17,18 but both these nomograms and the
surgical pathologic TNM staging system have two
major limitations: First, they cannot identify patients
with local disease who could spare the toxic effects of
unnecessary chemotherapy. Second, these conven-
tional models cannot predict the response to certain
chemotherapeutic regimens among patients with
systemic disease who truly require adjuvant systemic
treatment to reduce disease relapse and death rates.
In contrast to the proven eﬃcacy of adjuvant
cytotoxic chemotherapy in other adenocarcinomas
including colorectal, lung and breast cancer, no
conclusive data exist for gastric cancer. Many phase
III clinical trials have explored this approach in
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gastric cancer but the survival beneﬁt gained from the
use of adjuvant chemotherapy in gastric cancer has
not proven clinically signiﬁcant16,19–23 and therefore
adjuvant chemotherapy has not evolved as a part of
the standard of care in patients with gastric can-
cer.13,24
Level 1 evidence is considered the gold standard to
be used for building treatment guidelines and rec-
ommendations. Therefore, the large-scale, phase III
randomized MAGIC trial merits careful evaluation
particularly considering its impact in clinical practice.
MAGIC TRIAL: STRENGTHS, WEAKNESSES
AND LIMITATIONS
Cunningham et al.3 provide very important clinical
information based on the data of a large-scale trial
for a new therapy option in the treatment of gastric
cancer. Perioperative chemotherapy should be dis-
tinguished from both neoadjuvant (preoperative)
treatment, in which all adjuvant treatment protocol is
applied before surgery, and postoperative, where
treatment is administrated after surgery. In contrast
to neoadjuvant treatment, pathological responses,
either complete (pCR) or partial (pPR), to perioper-
ative chemotherapy cannot be clearly assessed be-
cause part of the chemotherapy is administrated
postoperatively. Thus, the only and major criterion of
clinical effectiveness for perioperative strategy is
clearance of disease and overall survival. In this phase
III trial, 503 patients with resectable adenocarcino-
mas of the stomach, esophagogastric junction, or
lower esophagus were randomly assigned to either
perioperative chemotherapy (three preoperative and
three postoperative cycles of ECF regimen) and sur-
gery, or surgery alone (253 patients). The primary
endpoint of the trial was overall survival.
The trial provided scientiﬁc evidence for improved
outcomes with the use of the ECF regimen. The 5-
year overall survival rate was increased by 13% when
perioperative chemotherapy was added to surgery.
This improvement in survival corresponds to a 25%
relative reduction in the risk of death (hazard ratio
0.75; 95% conﬁdence interval, 0.60 to 0.91;
p = 0.009). Progression-free survival also was im-
proved by chemotherapy. Moreover, perioperative
chemotherapy also achieved a decrease in tumor size
and reduction in the extent of identiﬁed nodal
metastases.
Despite the strengths, several intrinsic limitations
and weaknesses of the MAGIC trial should be con-
sidered:
(1) Generalizability, Lack of Tailoring Approach
For many clinical trials, generalizability poses
clinically important limitations. The MAGIC trial
was designed to detect a signiﬁcant diﬀerence in
overall survival between ECF chemotherapy plus
surgery over surgery alone for all tumor stages, II,
IIIA and IIIB, together. Subgroup analysis was out
of the scope of this study. Therefore, assessment of
beneﬁt according to tumor stage is diﬃcult. Partic-
ularly for early stage serosa-negative cancer, the
question of optimal treatment remains open. A re-
cent Japanese multicenter randomized trial for ser-
osa-negative cancer including node-positive disease
showed the 5-year disease-free survival rate in the
group receiving D2 surgery alone was 83% and the
overall survival was 86%.25 Also, D2 surgery alone
in Western patients with both serosa-negative and
node-negative disease was associated with recur-
rence rates less than 10%10 and high 10-year sur-
vival rates.12,26 These data show that many of
patients diagnosed with, and treated for, early-stage
cancer (local disease) are at low risk of recurrence,14
and can be cured with adequate surgical therapy
alone.27
Gene expression proﬁling of tumor tissue by
means of microarrays and reverse-transcriptase
polymerase chain reaction (RT-PCR) conﬁrms the
biologic and genetic heterogeneity of various cancer
types including the most common breast, lung,
gastric and other cancers.14,15,28–33 The heterogene-
ity of gastric cancer is also observed at a clinical
level. Even in patients with the same TNM stage
and similar clinical and pathologic features, the
outcome varies: some are cured, whereas in others,
the cancer recurs.1,15 Current conventional clinico-
pathologic staging is inadequate for predicting out-
comes and response to chemotherapy. Recently,
gene expression proﬁling studies have discovered
and validated gene signatures, which are now
commercially available for clinical use as biomar-
kers in breast cancer.30,33,34 Furthermore, large-scale
trials for new targeted therapies to improve the re-
sponse rates and survival for many cancer types
have become new standards of treatment.34 These
advances inﬂuence new gastric cancer research, but
it should be made clear that none of these bio-
markers or targeted drugs can be incorporated into
clinical practice for gastric cancer management. At
the present time only cytotoxic chemotherapy has
been tested in large-scale randomized phase III
clinical trials based on the current conventional
staging methods.
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(2) Completion of Treatment Protocol
As Cunningham et al.3 note, only 42% of patients
in the perioperative chemotherapy group completed
protocol treatment; 34% of patients who completed
preoperative chemotherapy and surgery did not begin
postoperative chemotherapy, predominantly owing
to early disease progression, patient request, or
postoperative complications. Early disease progres-
sion under ECF regimen reﬂects the aggressive biol-
ogy of gastric cancer and poses questions for the
possibility to respond to other regimen.
Toxicity assessment is important when chemo-
therapy is tested. Cunningham et al.3 found that
perioperative chemotherapy was associated with
acceptable rates of adverse events. Excluding patients
with neutropenia (23%), less than 12% of patients
suffered serious (grade 3 or 4) toxicity. Postoperative
morbidity (45%) and mortality (5.6%) shown in the
MAGIC trial are considered to be within an accept-
able range as a Western trial, though they may be
higher compared to those of trials from specialized
institutions.25,35–37
(3) New Chemotherapeutic Agents
Cunningham and colleagues3 note that the utilized
ECF regimen was developed in the late 1980s38,39 and
that there are now newer and less complex chemo-
therapy regimens with demonstrated activity against
advanced gastric cancer.40 New studies will test newer
regimens to assess whether these are better than ECF
regimen in the perioperative setting.
CHEMORADIATION
Postoperative chemoradiation in gastric cancer
with local and systemic eﬀects presents an interesting
therapeutic option. A large phase III trial of post-
operative therapy strongly suggested a beneﬁt from
the combination of irradiation and chemotherapy
after gastrectomy.41 This intergroup study 0116 (INT
0116), enrolled more than 550 patients who were
randomly assigned to surgery alone or surgery fol-
lowed by chemoradiation (ﬂuorouracil and leucovo-
rin plus external-beam radiation delivered to the
tumor bed and areas of draining lymph nodes). These
patients were at a signiﬁcant risk for relapse after
gastric resection — 85% had lymph node metastases
and 65% had stage T3 or T4 tumors. Median survival
in the surgery only and surgery plus chemoradiation
groups was 27 and 36 months, respectively
(p = 0.005 by the log-rank test); the corresponding
ﬁgures for disease-free survival were 19 and 30
months (p < 0.001). On the basis of these data,
postoperative chemoradiation has been accepted as a
standard of care in the USA among patients with
resected gastric adenocarcinomas.13
However, toxicity was high and the positive results
of this trial may be attributable to the eﬃcacy of
radiotherapy to control residual disease left by the
inadequately limited surgery. Indeed, less than 10%
of patients had D2 surgery, 54% had D0 surgery and
36% D1 surgery.41 D2 surgery alone is the preferred
treatment approach in specialized centers as it
achieves better or similar local-regional control as
D0/D1 surgery and chemoradiation 5,12,42 with a
lower side-effects proﬁle.35–37 Despite all these limi-
tations, postoperative chemoradiation makes an
attractive option for countries and areas where D1
surgery is the primary treatment. In these centers, the
oncologists decision is based on recurrence risk
estimates after surgery for associated surgical path-
ological tumor stage (pTNM). Risk of recurrence for
node-positive and serosa-positive disease after limited
surgery is high and can be reduced by chemoradia-
tion.1
CHALLENGES IN PRACTICE DECISIONS
As it provides level 1 evidence, it is expected that
the MAGIC study will inﬂuence the practice deci-
sions of surgical oncologists. The trial was well de-
signed and well conducted, and clinicians can have
conﬁdence in the ﬁndings of the study: Perioperatve
ECF regimen improved survival by acceptable tox-
icity rates. However, given that stage-speciﬁc sub-
group analysis was out of the scope of this study, the
key question for clinicians is whether a decision to
proceed with primary chemotherapy instead of pri-
mary surgery could harm more than beneﬁt some of
their patients. Given that patients with more ad-
vanced stages are at high risk of recurrence, it is
logical to expect that these patients are those who
would beneﬁt the most from a perioperative thera-
peutic strategy. By contrast, for patients with early,
serosa-negative cancer, who are at relatively low risk
of recurrence, the optimal treatment remains to be
deﬁned. Indeed, these patients could avoid a delay in
deﬁnitive surgery. Subsequently, decision on post-
operative adjuvant chemotherapy could be based on
exact surgical pathological staging (pT) taking the
following into consideration: tumor depth, location,
number of lymph nodes dissected and involved (pN
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stage), Laurens histological type (intestinal, diﬀuse),
and the extent of surgery (D1 or D2) performed.
These pathological features, as well as clinical char-
acteristics such age, can guide adjuvant treatment for
patients at higher risk of recurrence.1
CONCLUSIONS
The MAGIC study showed that the perioperative
ECF regimen, as compared with surgery alone, im-
proved clinical outcomes of patients with localized
stage II, IIIA and IIIB gastric cancer. After this ro-
bust ﬁnding, new studies are required to assess which
stage-speciﬁc subgroup mostly beneﬁts from adjuvant
chemotherapy in the perioperative, neoadjuvant or
postoperative setting.
Given the biological heterogeneity of gastric cancer
it is not surprising that the current clinicopathologic
staging methods and decisions on adjuvant treatment
are suboptimal. Current research focused on molec-
ular proﬁling of tumor tissue promises to discover
and validate novel gene signatures that will improve
recurrence risk stratiﬁcation and predict response to
various chemotherapeutic regimens. In addition to
novel clinical biomarkers, new targeted therapies will
further improve the clinical outcomes of patients with
gastric cancer in the future.
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